[Ip-health] New Tufts study on R&D costs

Dimasi, Joseph A. Joseph.Dimasi at tufts.edu
Sat Nov 15 02:15:36 PST 2014


Hi Jamie,

I assume that I can't enter to win the Tufts R&D Cost Estimate Prize Fund, but it's an interesting and amusing crowdsourcing type of experiment.  You might tally the results at the end and show the distribution of predictions.

Joe


--
-----------------------------------------------
Joseph A. DiMasi, Ph.D.
Director of Economic Analysis
Tufts Center for the Study of Drug Development Tufts University
75 Kneeland Street, Suite 1100
Boston, MA 02111
tel: 617-636-2116; fax: 617-636-2425
URL: http://csdd.tufts.edu
-----------------------------------------------

________________________________________
From: Ip-health [ip-health-bounces at lists.keionline.org] on behalf of Jamie Love [james.love at keionline.org]
Sent: Friday, November 14, 2014 4:14 PM
To: Outterson, Kevin
Cc: ip-health at lists.keionline.org listserve
Subject: Re: [Ip-health] New Tufts study on R&D costs

It will be interesting to see what "cost of capital" figures Tufts uses
this year.

Recently Gilead priced a series of bonds, $500 million at $2.35
percent maturing February 2020, $1,750M at 3.5 percent maturing February
2025 and $1,750M at 4.5 percent maturing February 2045.
_______________________________________________
Ip-health mailing list
Ip-health at lists.keionline.org
http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org



More information about the Ip-health mailing list